171 related articles for article (PubMed ID: 1671042)
1. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3.
Zabrecky JR; Lam T; McKenzie SJ; Carney W
J Biol Chem; 1991 Jan; 266(3):1716-20. PubMed ID: 1671042
[TBL] [Abstract][Full Text] [Related]
2. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
Alper O; Yamaguchi K; Hitomi J; Honda S; Matsushima T; Abe K
Cell Growth Differ; 1990 Dec; 1(12):591-9. PubMed ID: 1981143
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
[TBL] [Abstract][Full Text] [Related]
4. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC
Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090
[TBL] [Abstract][Full Text] [Related]
5. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
[TBL] [Abstract][Full Text] [Related]
6. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro.
Brodowicz T; Wiltschke C; Budinsky AC; Krainer M; Steger GG; Zielinski CC
Int J Cancer; 1997 Dec; 73(6):875-9. PubMed ID: 9399669
[TBL] [Abstract][Full Text] [Related]
7. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Cao H; Decker S; Stern DF
Oncogene; 1991 May; 6(5):705-11. PubMed ID: 1675782
[TBL] [Abstract][Full Text] [Related]
8. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.
Christianson TA; Doherty JK; Lin YJ; Ramsey EE; Holmes R; Keenan EJ; Clinton GM
Cancer Res; 1998 Nov; 58(22):5123-9. PubMed ID: 9823322
[TBL] [Abstract][Full Text] [Related]
9. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies.
Zhang H; Wang Q; Montone KT; Peavey JE; Drebin JA; Greene MI; Murali R
Exp Mol Pathol; 1999 Sep; 67(1):15-25. PubMed ID: 10493889
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
11. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.
Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI
Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992
[TBL] [Abstract][Full Text] [Related]
12. Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate.
Wu JT; Zhang P; Lyons BW; Wu LH
J Clin Lab Anal; 1998; 12(5):298-303. PubMed ID: 9773962
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells.
Tagliabue E; Castiglioni F; Ghirelli C; Modugno M; Asnaghi L; Somenzi G; Melani C; Ménard S
J Biol Chem; 2000 Feb; 275(8):5388-94. PubMed ID: 10681513
[TBL] [Abstract][Full Text] [Related]
15. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1).
Liu B; Sun D; Xia W; Hung MC; Yu D
J Natl Cancer Inst; 1997 Oct; 89(20):1524-9. PubMed ID: 9337349
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line.
Wu JT; Zhang P; Astill ME; Lyons BW; Wu LH
J Clin Lab Anal; 1995; 9(3):141-50. PubMed ID: 7602422
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.
Müller V; Thomssen C; Karakas C; Eustermann I; Ramirez Porras J; Coith C; Berger J; Löning T; Jänicke F; Pantel K
Int J Biol Markers; 2003; 18(1):13-20. PubMed ID: 12699058
[TBL] [Abstract][Full Text] [Related]
19. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP; Stern DF
Cancer Res; 1995 May; 55(9):1946-55. PubMed ID: 7728765
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
